From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged ...

The core reason for the analyst's cautious posture stems from ongoing regulatory challenges. Intellia is navigating the aftermath of a clinical hold placed by the U.S. Food and Drug Administration ...

Fintel reports that on January 6, 2026, Wolfe Research downgraded their outlook for Kymera Therapeutics (NasdaqGM:KYMR) from ...

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...

Summary • Kyverna Therapeutics shares fell 10.7% to $7.835 amid investor caution following recent announcements.• CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference despite a ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China rights to Zelgen’s lead oncology asset, alvetamig (ZG-006), a trispecific T-cell engager targeting delta-like ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

As of Friday, January 02, Outlook Therapeutics, Inc.’s OTLK share price has dipped by 55.57%, which has investors questioning ...